Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficacy and safety of CAR-T cell therapy in minorities

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Outcomes for minority and non-minority patients receiving CAR-T cell therapy.

Data availability

Data can be available upon request to the corresponding author.

References

  1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. https://doi.org/10.1056/NEJMoa1707447.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42. https://doi.org/10.1056/NEJMoa1914347.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502. https://doi.org/10.1016/s0140-6736(21)01222-8.

    CAS  Article  PubMed  Google Scholar 

  4. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380:45–56. https://doi.org/10.1056/NEJMoa1804980.

    Article  PubMed  Google Scholar 

  5. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. https://doi.org/10.1016/s0140-6736(20)31366-0.

    CAS  Article  PubMed  Google Scholar 

  6. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. https://doi.org/10.1056/NEJMoa1709866.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2116133.

    Article  PubMed  Google Scholar 

  8. Majhail NS, Nayyar S, Santibañez ME, Murphy EA, Denzen EM. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transpl. 2012;47:1385–90. https://doi.org/10.1038/bmt.2011.214.

    CAS  Article  Google Scholar 

  9. Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014;123:3553–62. https://doi.org/10.1182/blood-2013-07-517110.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Griffiths R, Gleeson M, Knopf K, Danese M. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010;10:625 https://doi.org/10.1186/1471-2407-10-625.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117:2530–40. https://doi.org/10.1002/cncr.25765.

    Article  PubMed  Google Scholar 

  12. Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, et al. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol. 2021;12:103–14. https://doi.org/10.5306/wjco.v12.i2.103.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge all the physician assistants and nurses on the bone marrow transplant and cellular therapy unit for their compassionate care for these patients. These studies were supported by grants from Izzy Englander, Jane and Myles Dempsey Family, Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program and the Leukemia and Lymphoma Society.

Author information

Authors and Affiliations

Authors

Contributions

Conception and design: AT, MG, AV, Data collection: MA, AT, Statistical analysis: KP, Initial manuscript draft: AT, MG, Manuscript revision: All authors. All authors have reviewed and approved the final version of the manuscript.

Corresponding authors

Correspondence to Ira Braunschweig or Mendel Goldfinger.

Ethics declarations

Competing interests

AV has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly and is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene and received honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. KG has received research funding from ionctura, SA and ADC therapeutics. AS has received honorarium from GLG, Guidepoint, Onclive, consultation fee from Janssen Pharmaceuticals, advisory board fee from Rigel Pharmaceuticals, research funding from Kymera Therapeutics. AT, MA, KP, RAS, NK, NS, IM, EF, SGL, RE, IB and MG have nothing to disclose.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thakkar, A., Abreu, M., Pradhan, K. et al. Efficacy and safety of CAR-T cell therapy in minorities. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01670-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-022-01670-1

Search

Quick links